Half year pro ad report 2019: Glaxo, J&J and Pfizer topped the list of biggest individual spenders

Marketers of cancer drugs spent far more than marketers of drugs for other conditions.

MM+M Staff

October 4, 2019

5:00 am

While imminent changes to Kantar Media’s methodology prompted the company not to calculate half-year ad-spending figures, the company did continue to track companies and therapeutic categories. Glaxo, J&J and Pfizer topped the list of biggest individual spenders in ad journals during the first half of 2019, while marketers of cancer drugs (antineoplastic agents) spent far more than marketers of drugs for other conditions.

From the October, 01 2019 Issue of MM+M - Medical Marketing and Media

From Our Partners

How AI and first-party data is transforming pharma customer engagement

Partner Content

How AI and first-party data is transforming pharma customer engagement

Using technology to improve audience segmentation, targeting and virtual interaction.

The importance of female representation in health

Partner Content

The importance of female representation in health

How to effect change and close the gender gap in healthcare.

The A100 Playbook Podcast | Real Chemistry: Visualizing the future: Art, science and AI innovation

Partner Content

The A100 Playbook Podcast | Real Chemistry: Visualizing the future: Art, science and AI innovation

Listen to Jack O’Brien of MM+M and Brandon Pletsch, president of scientific visualization at Real Chemistry, as they delve into the dynamic intersection of art, science and AI innovation in the field of scientific visualization.

Garbage in, garbage out — How health marketers can ensure the right information reaches patients and HCPs

Partner Content

Garbage in, garbage out — How health marketers can ensure the right information reaches patients and HCPs

This session with Justin Freid, chief marketing and innovation officer of CMI Media Group, and Daniel Nadler, founder of Open Evidence, will enlighten health brands to the possibilities of AI.